Home Value Investing Bronte Capital Feb Update: Gains On Medical Tech, Retail, And Mining Shrots

Bronte Capital Feb Update: Gains On Medical Tech, Retail, And Mining Shrots

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Bronte Capital Callisto Fund letter to partners for the month of February 2018.

The Bronte Capital Callisto Fund L.P. is a global long/short fund targeting double digit returns over the long term, advised by a performance orientated firm with a process and portfolio that is genuinely different. Objectives include lowering the risk of permanent loss of capital and providing global diversification without the market/drawdown risks typical of long-only funds. A highly diversified short book substantially reduces risk and enables profits to be made in tough markets.

Check out our H2 2017 hedge fund letters here.

In a turbulent month for global markets the Bronte Callisto fund rose by 1.0% (whereas the broad based ACWI global index was down by 4.2%). Despite this steep market decline our long portfolio proved resilient and, although being slightly leveraged, contributed less than half of the fall seen in the ACWI. The longs were more than made up for by our shorts. Major individual contributors were long positions in Herbalife and Interactive Brokers. Australian mining and retail shorts proved useful and a USA medical technology firm, the fund held a short position in, declined by more than 50%.

Bronte Capital Callisto Fund

Bronte Capital Callisto Fund

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Sheeraz Raza
Editor

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.